Inositol–Trisphosphate Reduces Alveolar Apoptosis and Pulmonary Edema in Neonatal Lung Injury
Male
0301 basic medicine
Caspase 8
Interleukin-6
Pulmonary Gas Exchange
Inositol Phosphates
Acute Lung Injury
Apoptosis
Pulmonary Edema
Ceramides
Amphiregulin
3. Good health
Pulmonary Alveoli
Disease Models, Animal
03 medical and health sciences
Animals, Newborn
Animals
Intercellular Signaling Peptides and Proteins
Female
Bronchoalveolar Lavage Fluid
Lung
Lymphotoxin-alpha
Glycoproteins
DOI:
10.1165/rcmb.2011-0262oc
Publication Date:
2012-03-09T05:20:46Z
AUTHORS (14)
ABSTRACT
D-myo-inositol-1,2,6-trisphosphate (IP3) is an isomer of the naturally occurring second messenger D-myo-inositol-1,4,5-trisphosphate, and exerts anti-inflammatory antiedematous effects in lung. Myo-inositol (Inos) a component IP3, thought to play important role prevention neonatal pulmonary diseases such as bronchopulmonary dysplasia acute lung injury (nALI). Inflammatory are characterized by augmented acid sphingomyelinase (aSMase) activity leading ceramide production, pathway that promotes increased vascular permeability, apoptosis, surfactant alterations. A novel, clinically relevant triple-hit model nALI was developed, consisting repeated airway lavage, injurious ventilation, lipopolysaccharide instillation into airways, every 24 hours. Thirty-five piglets were randomized one four treatment protocols: control (no intervention), alone, + Inos, IP3. After 72 hours mechanical lungs excised from thorax for subsequent analyses. Clinically, oxygenation ventilation improved, extravascular water decreased significantly with S IP3 intervention. In tissue, we observed aSMase concentrations, caspase-8 reduced alveolar epithelial expression interleukin-6, transforming growth factor-β1, amphiregulin (an factor), migration blood-borne cells particularly CD14(+)/18(+) (macrophages) airspaces, lower surface tensions IP3-treated but not Inos-treated piglets. We conclude admixture surfactant, improves gas exchange edema our suppression governing enzyme aSMase, this deserves clinical evaluation.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (49)
CITATIONS (14)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....